Back
EHRA Premium Access

Outpatient atrial fibrillation ablation: feasibility, safety and economic implications

Session: Atrial Fibrillation - Round 5 - Ablation
Topic: Rhythm Control, Catheter Ablation
Speaker: Professor J. Jimenez-Candil (Salamanca, ES)
Event: EHRA 2023

Congress Presentation

Add to my library

Like

About the speaker

Professor Javier Jimenez-Candil

IBSAL-Hospital Universitario de Salamanca, Salamanca (Spain)
0 follower

9 more presentations in this session

How different very late recurrence of atrial fibrillation 5 years after catheter ablation?

Speaker: Doctor S. Choi (Seoul, KR)

Access
Abstract
Slides
Like
Thumbnail

Progression and regression in the left atrial substrate in patients with atrial fibrillation: the PROGRESS-AF study

Speaker: Doctor L. Marcon (Brussels, BE)

Access
Abstract
Slides
Like
Thumbnail

One-year outcomes in patients undergoing very high-power short-duration temperature-controlled ablation for atrial fibrillation

Speaker: Doctor T. Strisciuglio (Naples, IT)

Access
Abstract
Slides
Like
Thumbnail

Insights into level of pulmonary vein isolation using pulsed-field ablation for atrial fibrillation and unexpected effects in the posterior wall.

Speaker: Doctor J. Osca Asensi (Valencia, ES)

Access
Abstract
Slides
Like
Thumbnail

Patient perspectives on same-day discharge following catheter ablation for atrial fibrillation: results from the FAST AFA trial

Speaker: Mr S. Koenig (Leipzig, DE)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Atrial Fibrillation - Round 5 - Ablation

Speakers: Professor J. Jimenez-Candil, Doctor S. Choi, Doctor L. Marcon, Doctor T. Strisciuglio, Doctor J. Osca Asensi...
Access
Like
Thumbnail

About the event

Image

EHRA 2023

16 April - 18 April 2023

Sessions Presentations

Congress
logo Image

Related content

EHRA Premium Access

One-year outcomes in patients undergoing very high-power short-duration temperature-controlled ablation for atrial fibrillation

17 April 2023

EHRA Premium Access

An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from an English NHS perspective

17 April 2023

EHRA Premium Access

1-yr outcomes from the MANIFEST-PF registry

16 April 2023

ESC 365 is supported by

novartis Explore sponsored resources